[Paper-level Aggregated] PMCID: PMC8255005

Evidence Type(s): Oncogenic

Summary: Mutation: D835Y | Summary: The D835Y mutation is part of the FLT3-TKD mutations that contribute to tumor development and progression in acute myeloid leukemia (AML).

Evidence Type: Oncogenic Mutation: F691 | Summary: The F691 mutation is implicated in the resistance to FLT3 inhibitors and contributes to tumor progression in acute myeloid leukemia (AML).

Gene→Variant (gene-first): FLT3(2322):D835Y FLT3(2322):F691

Genes: FLT3(2322)

Variants: D835Y F691

[Paper-level Aggregated] PMCID: PMC8255005

Evidence Type(s): Prognostic

Summary: Mutation: D835 | Summary: The D835 mutation is associated with poor prognosis in acute myeloid leukemia (AML).

Evidence Type: Prognostic Mutation: D835Y | Summary: The D835Y mutation is associated with poor prognosis in acute myeloid leukemia (AML).

Evidence Type: Prognostic

Gene→Variant (gene-first): FLT3(2322):D835 FLT3(2322):D835Y

Genes: FLT3(2322)

Variants: D835 D835Y

[Paper-level Aggregated] PMCID: PMC8255005

Evidence Type(s): Predictive

Summary: Mutation: F691L | Summary: The F691L mutation is described as a "gatekeeper" mutation that is resistant to most available FLT3 inhibitors, indicating its role in treatment resistance.

Evidence Type: Predictive Mutation: F691 | Summary: The F691 mutation is implicated in the resistance to FLT3 inhibitors and contributes to tumor progression in AML.

Gene→Variant (gene-first): FLT3(2322):F691L FLT3(2322):F691

Genes: FLT3(2322)

Variants: F691L F691

[Paragraph-level] PMCID: PMC8255005 Section: ABSTRACT PassageIndex: 1

Evidence Type(s): Prognostic, Predictive, Oncogenic

Summary: Evidence Type: Prognostic | Mutation: D835 | Summary: The D835 mutation is associated with poor prognosis in acute myeloid leukemia (AML). Evidence Type: Predictive | Mutation: F691L | Summary: The F691L mutation is described as a "gatekeeper" mutation that is resistant to most available FLT3 inhibitors, indicating its role in treatment resistance. Evidence Type: Oncogenic | Mutation: D835Y | Summary: The D835Y mutation is part of the FLT3-TKD mutations that contribute to tumor development and progression in AML. Evidence Type: Oncogenic | Mutation: F691 | Summary: The F691 mutation is implicated in the resistance to FLT3 inhibitors and contributes to tumor progression in AML.

Gene→Variant (gene-first): 2322:D835 2322:D835Y 2322:F691 2322:F691L

Genes: 2322

Variants: D835 D835Y F691 F691L

[Paper-level Aggregated] PMCID: PMC8255005

Evidence Type(s): Prognostic, Oncogenic, Functional

Justification: Prognostic: The text states that FLT3 mutations are associated with poor prognosis in acute myeloid leukemia (AML), indicating that the presence of these mutations can provide information about the likely outcome of the disease. Oncogenic: The mention of FLT3 mutations, including D835 and F691L, as common genetic alterations in AML suggests that these variants contribute to the development of cancer. Functional: The text discusses the resistance of FLT3 mutations (specifically F691L and D835Y) to FLT3 inhibitors and the mechanisms by which KX2-391 overcomes this resistance, indicating a functional role of these mutations in drug response.

Gene→Variant (gene-first): FLT3(2322):D835 FLT3(2322):D835Y FLT3(2322):F691 FLT3(2322):F691L

Genes: FLT3(2322)

Variants: D835 D835Y F691 F691L

[Paragraph-level] PMCID: PMC8255005 Section: ABSTRACT PassageIndex: 1

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the resistance of FLT3 mutations, specifically F691L, to FLT3 inhibitors and highlights the efficacy of KX2-391 in overcoming this resistance, indicating a correlation with treatment response. Oncogenic: The FLT3 mutations, including D835 and F691, are described as contributing to tumor development and progression in acute myeloid leukemia (AML), which supports their classification as oncogenic variants.

Gene→Variant (gene-first): 2322:D835 2322:D835Y 2322:F691 2322:F691L

Genes: 2322

Variants: D835 D835Y F691 F691L

[Paragraph-level] PMCID: PMC8255005 Section: ABSTRACT PassageIndex: 1

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the resistance of FLT3 mutations, specifically F691L, to FLT3 inhibitors and highlights the efficacy of KX2-391 in overcoming this resistance, indicating a correlation with treatment response. Oncogenic: The FLT3 mutations, including D835 and F691, are described as contributing to tumor development and progression in acute myeloid leukemia (AML), which supports their classification as oncogenic variants.

Gene→Variant (gene-first): 2322:D835 2322:D835Y 2322:F691 2322:F691L

Genes: 2322

Variants: D835 D835Y F691 F691L